Research to elucidate the gastrointestinal effects of Imeglimine.

2023 Fiscal Year Final Research Report

• Project/Area Number: 22K16414
• Research Category: Grant-in-Aid for Early-Career Scientists
• Allocation Type: Multi-year Fund
• Review Section: Basic Section 54040:Metabolism and endocrinology-related
• Research Institution: Kobe University
• Principal Investigator: Yamada Tomoko 神戸大学, 医学部附属病院, 助教 (70925247)
• Project Period (FY): 2022-04-01 – 2024-03-31
• Keywords: イメグリミン / 消化管 / FDG-PET/MRI / 腸内細菌 / 短鎖脂肪酸

Outline of Final Research Achievements

Through our study, we obtained results suggesting that Imeglimin, which structurally resembles Metformin, exhibits a certain degree of glucose excretory activity in the intestine, albeit to a lesser extent compared to Metformin. Furthermore, although both drugs have different effects on the gut microbiota, some of their metabolites may undergo similar changes, suggesting that they may affect intestinal glucose excretion. Further investigation into the relationship between gut microbiota and intestinal glucose excretory activity is planned for the future.

Free Research Field

Diabetes

Academic Significance and Societal Importance of the Research Achievements

イメグリミンは、グルコース応答性のインスリン分泌を促進すること等による血糖降下作用を有するが、同薬剤が消化管への糖排泄作用を有することが明らかとなれば、新規の血糖降下作用機序を明らかとすることとなり、臨床的意義は大きい。